Keytruda is indicated for the treatment of: [Select ALL That Apply].
a. Non-Small Cell Lung Cancer
b. Head and Neck Squamous Cell Cancer
c. Gastric Cancer
d. Esophageal Cancer
e. Cervical Cancer
The active ingredient found in Keytruda is Pembrolizumab. It is available in injection (100 mg/4 mL) form.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Keytruda is indicated for the treatment of:
b. Non-Small Cell Lung Cancer (NSCLC)
c. Small Cell Lung Cancer (SCLC)
d. Head and Neck Squamous Cell Cancer (HNSCC)
e. Classical Hodgkin Lymphoma (cHL)
f. Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
g. Urothelial Carcinoma
h. Microsatellite Instability-High Cancer
i. Gastric Cancer
k. Esophageal Cancer
l. Cervical Cancer
m. Hepatocellular Carcinoma (HCC)
n. Merkel Cell Carcinoma (MCC)
o. Renal Cell Carcinoma (RCC)
p. Endometrial Carcinoma
The usual recommended dose of Keytruda is 200 mg every 3 weeks or 400 mg every 6 weeks.
Immune-Mediated pneumonitis, colitis, hepatitis, endocrinopathies, hypophysitis, nephritis and renal dysfunction are commonly reported side effects of the drug.
www.pharmacyexam.com Try our Naplex Questions QBank.